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Abstract
Background: Previous studies have shown left-sided colorectal cancer (LCRC) and right-sided colorectal cancer
(RCRC) exhibit different molecular and clinicopathological features. We explored the association between the
primary tumor site and cetuximab efficacy in KRAS wild-type colorectal cancer (CRC).
Methods: This study enrolled a cohort of patients, who had received cetuximab treatment after two or more lines
of chemotherapy for KRAS wild-type (exon 2 nonmutant) metastatic CRC, from the databases of Taiwan Cancer
Registry (2004–2010) and National Health Insurance (2004–2011). Survival data were obtained from the National
Death Registry. Time to treatment discontinuation (TTD) and overall survival (OS) after the start of cetuximab
treatment were compared between patients with LCRC (splenic flexure to rectum) and RCRC (cecum to hepatic
flexure).
Results: A total of 969 CRC patients were enrolled. Among them, 765 (78.9 %) and 136 (14.0 %) patients had LCRC
and RCRC, respectively. Patients with LCRC, compared to patients with RCRC, had longer TTD (median, 4.59 vs. 2.
75 months, P = .0005) and OS (median, 12.62 vs. 8.07 months, P < .0001) after the start of cetuximab treatment.
Multivariate analysis revealed a right-sided primary tumor site was an independent predictor of shorter TTD
(adjusted hazard ratio [HR] = 1.32, using the LCRC group as a reference, 95 % confidence interval: 1.08–1.61, P = .0072)
and OS (adjusted HR = 1.45, 95 % CI: 1.18–1.78, P = .0003).
Conclusion: Our findings demonstrate that a left-sided primary tumor site is a useful predictor of improved cetuximab
efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 nonmutant) metastatic CRC.
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Background
Monoclonal antibodies targeting the epidermal growth
factor receptor (EGFR), either used alone, or a combin-
ation with cytotoxic agents have been demonstrated to
prolong survival in patients with metastatic colorectal
cancer (CRC) harboring KRAS wild-type or expanded
RAS [1–6]. However, not all patients experienced clinical
benefits of the anti-EGFR antibody treatment. These
studies have emphasized the importance of additional
predictive biomarkers for anti-EGFR antibody treatment.
Some predictive biomarkers, such as the gene expression
of EGFR ligands, have been reported to correlate with
patient responses after the anti-EGFR antibody treatment
[7, 8]. Besides, the primary resistance mechanisms of
cetuximab have been investigated rigorously. The negative
predictive roles of expanded RAS [KRAS (exons 2, 3,
and 4) and NRAS (exons 2, 3, and 4)] have been well
established, but other biomarkers, including BRAFV600E
mutation, amplification of KRAS, MET, and ERBB2,
and cross-talk with PI3K/Akt/PETN,, still remain to be
investigational [5, 6, 9–17].
Left- and right-sided CRC (LCRC and RCRC) have
different clinicopathological and molecular character-
istics [18–20]. Recently, clinical studies have shown
that a left-sided primary tumor site was associated
with the benefits of cetuximab, which is one of the anti-
EGFR antibodies, in patients with KRAS wild-type (exon 2
nonmutant) CRC [21, 22]. A subgroup analysis of the AIO
KRK-0306 trial revealed similar findings in patients with
expanded RAS wild-type CRC [23]. The definitive reasons
for this phenomenon remain unknown. Because most of
the aforementioned studies have investigated Western
populations, whether there is a similar association
between a primary tumor site and cetuximab efficacy in
the Taiwanese population has yet to be determined.
In Taiwan, patients have been reimbursed by the
National Health Insurance (NHI) for cetuximab ad-
ministration as the third-line or salvage therapy for
KRAS wild-type (exon 2 nonmutant) metastatic CRC
since August 1, 2009 [24]. In this study, we used the
Taiwan Cancer Registry (TCR) and NHI databases
concomitantly to evaluate the association between a
primary tumor site and the clinical benefits of cetuximab




The TCR database, which is organized and funded by
the Ministry of Health and Welfare, Taiwan, was imple-
mented in 1979, and an excellent coverage rate (97 %)
and data quality of cancer registry have been achieved
[25]. Hospitals were enlisted to report information on all
newly diagnosed cancers to the central registry office if
they had 50 or more inpatient beds. For monitoring the
patterns of cancer care and evaluates the outcomes of
cancer treatment, the central cancer registry (a long-
form database) has been modified since 2002 to include
detailed items of the stage at diagnosis and the first
course of treatment. Eighty hospitals, which account for
more than 90 % of total cancer cases in Taiwan, are in-
volved in the long-form registration.
NHI is a mandatory health insurance system, which
covers more than 99 % of Taiwan’s population. The NHI
database can provide patient medical records about diag-
nosis, clinical visits, admission, and drug prescriptions,
and the claims data are representative nationally. The
database has been developed as a tool for clinical cancer
research [26] and was used in our study to collect
complete records of the prescriptions of chemotherapy
and cetuximab. The NHI claims data on every patient
were examined thoroughly to determine the time of ini-
tiation and discontinuation of cetuximab and subsequent
chemotherapy.
The medical records were also linked to the National
Death Registry database to obtain mortality data and
were traced until December 31, 2012. Personal identities
were encrypted, and all data were analyzed anonymously
to comply with privacy regulations. The study data were
released after approval by the Data Release Review
Boards of the Health Promotion Administration and
Collaboration Center of Health Information Application,
Ministry of Health and Welfare, Executive Yuan, Taiwan.
The study protocol was approved by the Research Ethics
Committee of National Taiwan University Hospital.
Study population
A cohort of patients with a newly diagnosed CRC (ICD-
O-3: C180–C189, C199, C209, excluding morphology
codes representing lymphoma of 9590–9989 and Kaposi
sarcoma of 9140) from 2004 to 2010 was identified from
the TCR database. Patients were included in this study if
they met the following criteria: [1] pathologically proven
single primary CRC; [2] aged ≥ 18 years; [3] having known
the cancer stage at diagnosis, according to the American
Joint Committee on Cancer system, Sixth Edition; [4] hav-
ing received standard chemotherapy (oxaliplatin, irinote-
can, and one of the following: capecitabine, uracil–tegafur,
or fluorouracil); and [5] having received more than one
prescription of cetuximab as the third-line or salvage
treatment for metastatic CRC and the first prescription of
cetuximab during August 1, 2009 to December 31, 2011.
In Taiwan, since August 1, 2009, cetuximab treatment
services have been reimbursed by the NHI for patients
with KRAS wild-type (exon 2 nonmutant) metastatic
CRC who failed to respond to oxaliplatin, irinotecan,
and fluorouracil. Capecitabine and uracil–tegafur are
commonly recognized alternatives to fluorouracil; thus,
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some patients who used capecitabine or uracil–tegafur in-
stead of fluorouracil were also reimbursed. Physicians had
to provide documentation of pathology, images, prior
chemotherapy records, and KRAS mutation tests when
applying to the NHI for cetuximab reimbursement. The
amount of cetuximab for which reimbursement would be
provided at a given time was a standard dosage (250 mg/
m2 per week) for 9 weeks. The physicians were mandated
to submit image reports supporting the presence of a
responsive or stable disease after cetuximab treatment to
apply for the second round of 9-week cetuximab usage.
The maximal amount of reimbursed cetuximab treatment
by the NHI was the standard dosage for 18 weeks.
Study variables and outcomes
The baseline characteristics of the study patients, including
age (grouped as < 50 years, 50–64 years, and > 65 years),
sex, histology, the cancer stage at diagnosis, cancer grading,
and primary tumor site were retrieved from the TCR data-
base. Patients were classified into either an RCRC or LCRC
group, where RCRC was defined as cancer from the cecum
to hepatic flexure of the colon (ICD-O-3: C180–C183), and
LCRC (ICD-O-3: C185, 186, 187, 199, 209) was defined as
cancer from the splenic flexure of the colon to the rectum.
The main endpoints were overall survival (OS) and
time to treatment discontinuation (TTD). OS was deter-
mined from the initiation of cetuximab treatment to the
time of death or until December 31, 2012, whichever
came first. TTD was calculated from the initiation of
cetuximab to the date of the final cetuximab prescrip-
tion, the date of death, or December 31, 2012, whichever
came first.
Statistical analysis
The mean demographic and clinical characteristics of
patients with LCRC and RCRC at baseline were com-
pared using the chi-squared test for categorical variables
and the two-sample t test for continuous variables. OS
and TTD were estimated using the Kaplan–Meier
method, and comparisons were made using the log-rank
test. The Cox proportional hazard model was used to
estimate adjusted hazard ratios (HRs) and 95 % confi-
dence intervals (CIs). The age, sex, histology, cancer
stage at diagnosis, and tumor grade of the patients were
Fig. 1 Consort diagram illustrating the treatment flow of patients
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adjusted using the Cox proportional hazard model. For
comparison, results with a two-sided P value of less than
.05 were considered statistically significant. Statistical
software, SAS (Version 9.3, SAS Institute, Cary, NC,
USA), was used for all statistical analyses.
Results
A total of 58 736 patients with a newly diagnosed CRC
were identified from the TCR database; among them,
969 patients met the inclusion criteria and were enrolled
in this study (Fig. 1). The study population comprised
591 (61 %) males with a median age at cetuximab treat-
ment of 60 years, 938 (96.8 %) patients with adenocar-
cinoma, and 136 (14 %), 58 (6 %), and 765 (78.9 %)
patients with right-sided, transverse, and left-sided pri-
mary tumor sites, respectively (Table 1). Five hundred
and fifty (56.8 %) patients had initial stage IV CRC. The
mean time interval from diagnosis to the first cetuximab
prescription was 26.4 months. Nearly all (99.2 %)
patients received cetuximab treatment in combination
with chemotherapy.
Patients with a primary site of cancer at the trans-
verse colon or an unspecified site were excluded from
survival analysis. Compared with patients with LCRC,
patients with RCRC were mostly female (45.6 % vs.
36.9 %, P = .0536) and showed more mucinous adeno-
carcinoma (11 % vs. 2.7 %, P < .0001) and grade 3
tumors (20.6 % vs. 8.5 %, P = .002) (Table 2). The
median follow-up time was 11.5 months. Patients
with LCRC had significantly longer OS (median, 12.62
vs. 8.07 months, P < .0001) and TTD (median, 4.59 vs.
2.75 months, P = .0005) than those of patients with
RCRC (Fig. 2). After we adjusted the covariates,
including age at cetuximab treatment, sex, histology,
stage at diagnosis, and tumor grade, RCRC was an
independent predictor of overall mortality (adjusted
HR = 1.45 [using the LCRC group as a reference], 95 %
confidence of interval (CI): 1.18–1.78, P = .0003) after
cetuximab treatment and treatment discontinuation (ad-
justed HR = 1.32, 95 % CI: 1.08–1.61, P = .0072) (Table 3).
Discussion
In this study, we found that patients with LCRC had
more clinical benefits of the third-line or salvage cetuxi-
mab treatment regarding TTD and OS than did patients
with RCRC. In addition, multivariate analysis demon-
strated that a primary tumor site was an independent
predictor of patient prognosis. TTD, instead of trad-
itional progression-free survival (PFS), was used as one
of the endpoints of the study because the maximal reim-
bursement amount of cetuximab was the standard 18-
week dosage and the time of disease progression in
patients were not recorded in NHI and TCR databases.
Our study was in agreement with several studies on
Western population. In an exploratory analysis of NCIC
CTG CO.17, Brulé et al demonstrated that a left-sided
tumor site (splenic flexure to rectosigmoid colon) is a
strong predictive factor for long PFS in patients with
refractory, metastatic, and KRAS wild-type (exon 2)
colon cancer receiving cetuximab treatment [27]. Two
AIO KRK studies (0104 and 0306) demonstrated that in
populations with either KRAS wild-type (codon 12/13)
or expanded RAS, a left primary tumor site was associ-
ated with long PFS and OS in untreated metastatic CRC
patients who received cetuximab-containing regimens
[21, 23]. However, based on our research, the current
Table 1 Patient characteristics of all studied patients
N (%)




Age at treatment (years)
Mean (SD) 60.01 (12.11)
Median (min, max) 60 (22, 96)
Side
Left (splenic flexture to rectum) 765 (78.9)















Time interval from diagnosis date to first prescription of Cetuximab
Mean months (SD) 26.4 (15.3)
Cetuximab combination with chemotherapy 961 (99.2)
Chemotherapy after end of Cetuximab 532 (54.9 %)
Death 806 (83.2)
Follow-up (months)
Mean (SD) 12.8 (8.6)
Median (min, max) 11.3 (0.1, 39.4)
Abbreviation: SD standard deviation
aby American Joint Cancer Committee on Cancer (AJCC) system, 6th edition
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Table 2 Patient characteristics of LCRC and RCRC
Total RCRC LCRC
N (%) N (%) N (%) P value
Patient Number 901 (100.0) 136 (100.0) 765 (100.0)
Gender
Male 557 (61.8) 74 (54.4) 483 (63.1) .0536
Female 344 (38.2) 62 (45.6) 282 (36.9)
Mean age at treatment (years)
Mean (SD) 59.95 (12.02) 61.39 (11.91) 59.70 (12.02) .0992
Median (min, max) 60 (22, 96) 61 (22, 96) 60 (26, 90)
Age group (years)
<50 163 (18.1) 18 (13.2) 145 (19.0) .2256
50-64 420 (46.6) 64 (47.1) 356 (46.5)
65+ 318 (35.3) 54 (39.7) 264 (34.5)
Histology
Mucinous adenocarcinoma 36 (4.0) 15 (11.0) 21 (2.7) < .0001
Non-mucinous adenocarcinoma 836 (92.8) 115 (84.6) 721 (94.2)
Others 29 (3.2) 6 (4.4) 23 (3.0)
Grade
1 43 (4.8) 5 (3.7) 38 (5.0) .0002
2 689 (76.5) 90 (66.2) 599 (78.3)
3 93 (10.3) 28 (20.6) 65 (8.5)
Undifferentiated or Unknown 76 (8.4) 13 (9.6) 63 (8.2)
Stage at diagnosisa
I-III 396 (44.0) 64 (47.1) 332 (43.4) .4281
IV 505 (56.0) 72 (52.9) 433 (56.6)
Cetuximab combination with chemotherapy 893 (99.1) 135 (99.3) 758 (99.1)
Chemotherapy after end of cetuximab 495 (54.9) 61 (44.9) 434 (56.7)
Death 747 (82.9) 121 (89.0) 626 (81.8)
Follow-up (months)
Mean (SD) 13.0 (8.6) 10.1 (8.0) 13.5 (8.6)
Median (min, max) 11.5 (0.1, 39.4) 8.1 (1.2, 34.8) 12.5 (0.1, 39.4)
Abbreviation: SD standard deviation
aby American Joint Cancer Committee on Cancer (AJCC) system, 6th edition
Fig. 2 Kaplan-Meier analysis of time to treatment discontinuation and overall survival. Kaplan-Meier analysis of time to treatment discontinuation
(a) and overall survival (b) among patients who received cetuximab as salvage therapy for advanced KRAS wild type (exon 2 non-mutant) CRC.
Patients were divided according to primary tumor site (left side: splenic flexture to rectum; right side: cecum to hepatic flexture). The P values
were conducted using the log-rank test
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study is the first to demonstrate an association between
the primary tumor site of CRC and the clinical benefits
of cetuximab treatment in the East Asian population.
The definitive reasons for different clinical benefits of
cetuximab treatment in these patients remain unclear. Sev-
eral studies have revealed different molecular and clinico-
pathological features between left-sided and right-sided
CRC [18–20, 28]. For example, RCRC is characterized by
features such as microsatellite instability phenotype, RAS
mutation, mitogen-activated protein kinase activation,
BRAFV600E mutation, BRAF-like characteristics, and the
CpG island methylator phenotype [18, 20]. By contrast,
LCRC is characterized by chromosomal instability, amplifi-
cation of EGFR and ERBB2, EGFR pathway upregulation,
and WNT, MYC, and SRC pathway activation [18].
Because the aforementioned association of a primary tumor
site with cetuximab treatment was also noted in an
expanded RAS wild-type population, primary expanded
KRAS (exon 2, 3, 4) or NRAS (exon 2, 3, 4) mutations may
not explain the different clinical benefits of cetuximab treat-
ment in patients with different primary tumor sites.
Whether emergence of new KRAS mutations played a role
is unknown. Several studies have suggested that the
high gene expression of EGFR ligands (epiregulin and
amphiregulin) predicted favorable outcomes in patients
receiving cetuximab treatment, which may explain our
findings [7, 8]. BRAFV600E has been shown to have a
strong causal relationship with resistance to anti-EGFR
antibodies in preclinical models, but the correlation in clin-
ical settings is not statistically significant [9, 12, 13, 17].
There are several gene alterations involved in the EGFR sig-
naling pathway beyond RAS and BRAF mutations, which
converge biochemically on activation of RAS/MEK/ERK,
but their relevance to the de novo resistance to anti-EGFR
antibody treatment remains undetermined.
Although many studies have shown promising efficacies
of anti-EGFR antibody therapy in KRAS or expanded RAS
wild-type metastatic CRC, the heterogeneity of CRC
should be considered if different benefits were found in
patient subsets. Our study showed a poor cetuximab treat-
ment efficacy in patients with KRAS wild-type RCRC
(cecum to hepatic flexure), thus emphasizing an urgent
unmet clinical need in such patients. Bevacizumab is a
vascular endothelial growth factor inhibitor that has
shown clinical benefits in patients with advanced CRC
[6, 29]. In the post hoc analysis of an AIO KRK-0306
trial, patients with RCRC appeared to have a favorable
outcome in the bevacizumab plus FOLFIRI arm [23].
Whether bevacizumab is a superior choice for patients
with RAS wild-type RCRC must be validated in a ran-
domized clinical trial. Recently, a combination of an
anti-EGFR antibody and an MEK inhibitor has been
expected to overcome the resistance emerging from
KRAS mutations or cross talk with the PI3K/Akt/PETN
pathway after anti-EGFR antibody treatment, and the
upfront use of these regimens could be considered in
these patient subsets [30].
There are limitations of the current study. First, this
was a nationwide cohort study, and we identified
patients with KRAS wild-type CRC according to their
Table 3 Multivariate analyses of overall mortality and treatment discontinuation. Multivariate analysis by a Cox’s proportional hazard
model for hazard ratios of overall mortality and treatment discontinuation in patients received cetuximab as salvage treatment for
advanced KRAS wild type (exon 2 non-mutant) CRC
Overall mortality Treatment discontinuation
Variable Adjusted HR (95 % CI) P value Adjusted HR (95 % CI) P value
RCRC (vs. LCRC) 1.45 (1.18, 1.78) .0003 1.32 (1.08, 1.61) .0072
Female (vs. male) 1.04(0.90, 1.21) .5869 1.01 (0.87, 1.16) .9413
Age (vs. < 50 y) .2962 .0783
50-64 0.86 (0.70, 1.06) 0.80 (0.66, 0.98)
65+ 0.94 (0.76, 1.17) 0.82 (0.67, 1.01)
Stage IV at diagnosis (vs. I-III)a 1.11 (0.95, 1.28) .1887 1.08 (0.94, 1.25) .2916
Histology (vs. others) .1096 .1524
Mucinous adenocarcinoma 1.55 (0.91, 2.65) 1.69 (0.99, 2.89)
Non-mucinous adenocarcinoma 1.04 (0.69, 1.59) 1.42 (0.93, 2.18)
Grade (vs. I) .0009 .0023
II 1.24 (0.88, 1.76) 1.02 (0.74, 1.40)
III 1.82 (1.21, 2.74) 1.39 (0.95, 2.05)
Undifferentiated or unknown 1.75 (1.15, 2.65) 1.50 (1.01, 2.22)
Abbreviation: HR hazard ratio, CI confidence interval, RCRC right sided colorectal cancer (cecum to hepatic flexture), LCRC left sided colorectal cancer (splenic
flexture to rectum), SD standard deviation
aby American Joint Cancer Committee on Cancer (AJCC) system, 6th edition
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usage of reimbursed cetuximab. Thus, we could not per-
form expanded KRAS or NRAS analyses during the study
period. Moreover, the schedule and dosage of cetuximab
could not be uniform, which might have confounded
our results, particularly for TTD. Second, bevacizumab
was not reimbursed for advanced CRC until June 1,
2011 (in a first-line setting only) but was approved by
the Taiwan Food and Drug Administration in 2005. Pre-
vious studies have shown that patients with different pri-
mary tumor sites might derive different benefits from
bevacizumab combined with chemotherapy [23, 31]. A
few patients who used self-paid bevacizumab might have
confounded our results. Third, some experts have postu-
lated that molecular features of CRC change gradually
with the bowel; thus, it might be oversimplified to clas-
sify heterogeneous CRC as only a left- or right-sided
group [32]. Moreover, although Brulé et al revealed pri-
mary tumor site was not a prognostic factor in refractory
CRC patients in NCIC CO.17, the prognostic role of it
in KRAS or RAS wild type, metastatic CRC patients
remains unknown [22]. We could not exclude the prob-
ability that left-sided tumor was a favorable prognostic
factor. The long interval between TTD and OS may also
imply other confounding factors were ignored. However,
our study clearly demonstrated that the primary tumor
site (left- or right-sided) is a useful biomarker for
predicting the prognosis after cetuximab treatment in
patients with advanced KRAS wild-type (exon 2 nonmu-
tant) CRC. Furthermore, our nationwide study had the
advantages of evaluating OS and preventing selection
bias, because no eligible patients were lost to follow-up.
Conclusion
This study demonstrated that a left-sided primary tumor
site is a useful predictive marker for improved cetuximab
efficacy for the third-line or salvage treatment among
patients with KRAS wild-type (exon 2 nonmutant) meta-
static CRC. Our study results emphasize the unmet
medical needs in patients with a right-sided tumor site
and provide factual survival data for future clinical trials.
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